
    
      Open-label, multicenter, randomized phase II trial over approx 6.5 months of neoadjuvant
      treatment with letrozole with or without zoledronic acid in postmenopausal patients with
      primary breast cancer. A total of approximately 850 patients were originally planned to be
      enrolled; primary study endpoint was the objective response rate (according to modified
      RECIST criteria) after 6 months of treatment. After the core study, patients willing to
      participate were followed-up for further 5 years.
    
  